1. [1] Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156. [DOI:10.1002/ijc.1440] [PMID]

2. [2] Harirchi I, Karbakhsh M, Kashefi A, Momtahen AJ. Breast cancer in Iran: results of a multi-center study. Asian Pac J Cancer Prev 2004; 5: 24-27.

3. [3] Yaghmaei S, Bani Hashemi G, Ghorbani R. Survival rate following treatment of primary breast cancer in Semnan, Iran (1991-2002). Koomesh 2008; 19: 111-116. (Persian).

4. [4] Kluger HM. Is Catherin expression correlated with metastases.2005; 25: 452-457.

5. [5] Montagna E, Bagnardi V, Rotmensz N, Viale G, Renne G, Cancello G, et al. Breast cancer subtypes and outcome after local and regional relapse. Ann Oncol 2012; 23: 324-331. [DOI:10.1093/annonc/mdr129] [PMID]

6. [6] Hajihosseini M, Amini P, Shahdoust M, Faradmal J, Sadeghyfar M, Sedighi-Pashaki A. Application of log-normal parametric model in disability structure to predict metastasis and death due to breast cancer. Koomesh 2016;18: 95-101. (Persian).

7. [7] Kumar V, Abbas AK, Fausto N. Robbins y Cotran. Patología estructural y funcional: Elsevier; 2005; p. 1120-1151.

8. [8] Aitken S, Thomas J, Langdon S, Harrison D, Faratian D. Quantitative analysis of changes in ER, PR and HER2 expression in primary breas cancer and paired nodal metastases. Ann Oncol 2010; 21: 1254-1261. [DOI:10.1093/annonc/mdp427] [PMID]

9. [9] Cook R J, Lawless JF. Analysis of repeated events. Stat Methods Med Res 2002; 11: 141-166. [DOI:10.1191/0962280202sm278ra] [PMID]

10. [10] Osmani F, Hajizadeh E, Mansoori P. Estimation of seasonal effect on the psoriasis recurrence using time dependent coefficient rates model for recurrent events. J Dermatol Cosmetic 2015; 6: 23-30. (Persian)

11. [11] Liu L, Wolfe RA, Huang X. Shared frailty models for recurrent events and a terminal event. Biometrics 2004; 60: 747-756. [DOI:10.1111/j.0006-341X.2004.00225.x] [PMID]

12. [12] R. L. Prentice, B. J. Williams, and A. V. Peterson, ''On the regression analysis of multivariate failure time data,'' Biometrika 1981; 68: 373-389. [DOI:10.1093/biomet/68.2.373]

13. [13] Osmani F, Hajizadeh E, Mansoori P. Use of smoothing methods for estimating the coefficients of time dependent rate models in survival analysis and its application in psoriasis disease. Iran J Epidemiol 2016; 12: 36-46.

14. [14] Mansouri P, Hajizadeh E, Osmani F. Analysis of risk factors for psoriasis recurrence using proportional rates model. J Skin Stem Cell 2014; 1. (Persian). [DOI:10.17795/jssc25808]

15. [15] Akbari ME, Mozaffar M, Heidari A, Zirakzadeh H, Akbari A, Akbari M, et al. Recurrence and survival effect in breast conserving surgery: what are the predictive and/or prognostic factors? Iran J Cancer Prev 2011; 4: 49-54. (Persian).

16. [16] Aalen O, Borgan O, Gjessing H. Survival and event history analysis: a process point of view: Springer; 2013

17. [17] Osmani F, Hajizadeh E, Rasekhi A, Akbari M E. Multivariate Joint Frailty Models for Modeling Multiple Recurrent Events and Its Application in Breast Cancer. RJMS 2019; 25: 71-79. (Persian).

18. [18] Osmani F, Hajizadeh E, Rasekhi A. Association between multiple recurrent events with multivariate modeling: a retrospective cohort study. J Res Health Sci 2018; 18. (Persian).

19. [19] Heitz F, Rochon J, Harter P, Lueck HJ, Fisseler-Eckhoff A, Barinoff J, et al. Cerebral metastases in metastatic breast cancer: disease specific risk factors and survival. Ann Ancol 2011; 22: 1571-1581. [DOI:10.1093/annonc/mdq625] [PMID]

20. [20] Osmani F, Hajizadeh E, Mansoori P. Estimation of seasonal effect on the psoriasis recurrence using time dependent coefficient rates model for recurrent events. Dermatol Cosmetic 2015; 6. (Persian).

21. [21] Gohari MR, Mahmoudi M, Kazem M, Pasha E, Khodabakhshi R. Recurrence in breast cancer analysis with frailty model. Saudi Med J 2006; 27: 1187-1193.

22. [22] Mirzaei HR, Hajian S, Mofid B. The role of prognostic factors on breast cancer recurrence in patients at radiation oncology ward in imam hossain hospital. Iran J Breast Cancer 2008; 1. (Persian).

23. [23] Dawood S, Broglio K, Esteva F, Ibrahim N, Kau SW, Islam R, et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 2008; 19: 1242-1248. [DOI:10.1093/annonc/mdn036] [PMID]

24. [24] Rondeau V, Mathoulin-Pélissier S, Tanneau L, Sasco AJ, MacGrogan G, Debled M. Separate and combined analysis of successive dependent outcomes after breast-conservation surgery: recurrence, metastases, second cancer and death. BMC Cancer 2010; 10: 697-709. [DOI:10.1186/1471-2407-10-697] [PMID] [PMCID]

25. [25] Gohari MR, Mahmoudi M, Mohammed K, Pasha E, Khodabakhshi R. Recurrence in breast cancer. Saudi Med J 2006; 27: 1187-1193.

26. [26] Mansouri P, Hajizadeh E, Osmani F. Analysis of risk factors for psoriasis recurrence using proportional rates model. J Skin Stem Cell 2014; 1. (Persian). [DOI:10.17795/jssc25808]

27. [27] Osmani F, Hajizadeh E, Rasekhi A, Akbari ME. Analyzing relationship between local and metastasis relapses with survival of patients with breast cancer: a study using joint frailty model. Int J Cancer Manag 2018. (Persian) [DOI:10.5812/ijcm.81783]